Equities research analysts expect Tricida Inc (NASDAQ:TCDA) to post earnings per share of ($0.89) for the current quarter, Zacks reports. Zero analysts have made estimates for Tricida’s earnings. The lowest EPS estimate is ($0.94) and the highest is ($0.83). Tricida reported earnings per share of ($0.66) in the same quarter last year, which suggests a negative year-over-year growth rate of 34.8%. The company is expected to announce its next quarterly earnings report after the market closes on Thursday, November 14th.
According to Zacks, analysts expect that Tricida will report full-year earnings of ($3.53) per share for the current year, with EPS estimates ranging from ($3.65) to ($3.40). For the next year, analysts forecast that the business will report earnings of ($3.73) per share, with EPS estimates ranging from ($4.10) to ($3.35). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Tricida.
Tricida (NASDAQ:TCDA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.12.
In related news, Director Robert J. Alpern sold 1,832 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $38.98, for a total transaction of $71,411.36. Also, CEO Gerrit Klaerner sold 10,255 shares of the business’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $30.69, for a total value of $314,725.95. In the last quarter, insiders sold 81,926 shares of company stock valued at $2,782,523. Company insiders own 66.70% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of TCDA. Price T Rowe Associates Inc. MD boosted its holdings in Tricida by 69.8% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,901,325 shares of the company’s stock valued at $153,946,000 after acquiring an additional 1,603,231 shares during the period. Vanguard Group Inc. boosted its holdings in Tricida by 49.1% during the 2nd quarter. Vanguard Group Inc. now owns 2,246,304 shares of the company’s stock valued at $88,639,000 after acquiring an additional 740,141 shares during the period. Vivo Capital LLC boosted its holdings in Tricida by 82.4% during the 2nd quarter. Vivo Capital LLC now owns 1,424,525 shares of the company’s stock valued at $56,212,000 after acquiring an additional 643,340 shares during the period. JPMorgan Chase & Co. boosted its holdings in Tricida by 47.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,500,373 shares of the company’s stock valued at $57,314,000 after acquiring an additional 486,178 shares during the period. Finally, BlackRock Inc. boosted its holdings in Tricida by 23.4% during the 2nd quarter. BlackRock Inc. now owns 2,356,417 shares of the company’s stock valued at $92,984,000 after acquiring an additional 447,562 shares during the period. Institutional investors own 80.67% of the company’s stock.
Shares of NASDAQ TCDA traded down $0.30 during trading on Thursday, hitting $38.98. The company had a trading volume of 131,700 shares, compared to its average volume of 263,408. The firm has a market capitalization of $1.95 billion, a P/E ratio of -8.40 and a beta of 0.85. The company has a debt-to-equity ratio of 0.11, a quick ratio of 14.22 and a current ratio of 14.23. The stock has a 50 day simple moving average of $34.20 and a 200 day simple moving average of $34.43. Tricida has a 12 month low of $19.43 and a 12 month high of $42.80.
Tricida Company Profile
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Read More: Leveraged Buyout (LBO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.